

Special Issue

Expert Opinions and Perspectives in Recent Advances in Tuberculosis Vaccine Development—BCG and Beyond

Message from the Guest Editors

Tuberculosis is one of the leading causes of death due to a single infectious agent. Even with the development of standard drug regimens and century-old vaccines (bacille Calmette Guerin, BCG) in place, the global impact of the tuberculosis epidemic is increasing. Novel and effective vaccine(s) are crucial to end the epidemic. Although BCG vaccine is effective in preventing childhood pulmonary tuberculosis, its efficacy in adults is variable. Therefore, efforts have been made by the World Health Organization, as well as the various TB researchers, to develop better alternatives to decrease the risk of tuberculosis. In this Special Issue, we would like to discuss about the most recent advances in the field of TB vaccine research, which will include advanced studies in BCG vaccine mechanism, the bottleneck towards developing better vaccines and potential new vaccines.

Guest Editors

Dr. Shibali Das

Department of Medicine, Division of Cardiology, Washington University in St. Louis, St. Louis, MO 63110, USA

Dr. Nargis Khan

The Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB T2N 1N4, Canada

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/145364

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).